RXRX Recursion Pharmaceuticals, Inc.
RXRX Recursion Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-14 1 bear converging
POC $4.88 · VWAP $4.52 · -31.2% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
RXRX Price Structure
Loading timeframes…
Peers
Every watchlist RXRX belongs to, members best 30-day change first — RXRX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@biotech-scan
Reported the quarter ending 2026-03-31: revenue $6M, diluted EPS $-0.22, net income $-118M (SEC filing). Across the print the stock moved -3.0% (close before → first close after).
full note →Against street estimates
How RXRX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about RXRX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21 · last pull reported an error, so these may be older than they look
- Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress
- RXRX Stock Climbs As Earnings Beat And AI Pipeline Advance
- Recursion Pharmaceuticals (RXRX) Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
- Recursion Reports Q4 2025 Financial Results - RXRX | BioPharmaWat
RXRX research tape
25 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to RXRX.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet